JP2022542434A5 - - Google Patents
Info
- Publication number
- JP2022542434A5 JP2022542434A5 JP2022506384A JP2022506384A JP2022542434A5 JP 2022542434 A5 JP2022542434 A5 JP 2022542434A5 JP 2022506384 A JP2022506384 A JP 2022506384A JP 2022506384 A JP2022506384 A JP 2022506384A JP 2022542434 A5 JP2022542434 A5 JP 2022542434A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancers
- syndrome
- vitiligo
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881026P | 2019-07-31 | 2019-07-31 | |
| US62/881,026 | 2019-07-31 | ||
| PCT/US2020/044558 WO2021022186A1 (en) | 2019-07-31 | 2020-07-31 | Deuterated mk2 pathway inhibitors and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022542434A JP2022542434A (ja) | 2022-10-03 |
| JP2022542434A5 true JP2022542434A5 (enExample) | 2023-07-19 |
Family
ID=74228512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506384A Ceased JP2022542434A (ja) | 2019-07-31 | 2020-07-31 | 重水素化ｍｋ２経路阻害剤およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12403141B2 (enExample) |
| EP (1) | EP4003344A4 (enExample) |
| JP (1) | JP2022542434A (enExample) |
| KR (1) | KR20220041180A (enExample) |
| CN (1) | CN114206339A (enExample) |
| AU (1) | AU2020319879A1 (enExample) |
| BR (1) | BR112022001324A2 (enExample) |
| CA (1) | CA3149304A1 (enExample) |
| IL (1) | IL290045A (enExample) |
| MX (1) | MX2022001151A (enExample) |
| PH (1) | PH12022550029A1 (enExample) |
| WO (1) | WO2021022186A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220161396A (ko) * | 2020-03-27 | 2022-12-06 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형 |
| BR112023019861A2 (pt) | 2021-03-31 | 2023-11-07 | Xinthera Inc | Inibidores de mk2 e usos dos mesmos |
| EP4367099A4 (en) | 2021-07-09 | 2025-06-04 | Xinthera, Inc. | Pyridinone mk2 inhibitors and uses thereof |
| WO2023001282A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
| CN116444492B (zh) * | 2021-12-29 | 2026-03-03 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| EP4464694A4 (en) | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN116444493A (zh) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | 含双并环类衍生物、其制备方法和应用 |
| WO2023150709A2 (en) * | 2022-02-04 | 2023-08-10 | Aclaris Therapeutics, Inc. | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds |
| CN119384410A (zh) * | 2022-03-03 | 2025-01-28 | 深圳信立泰药业股份有限公司 | 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用 |
| EP4650347A1 (en) * | 2023-01-13 | 2025-11-19 | Shanghai Meiyue Biotech Development Co., Ltd. | Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof |
| JP2026504073A (ja) * | 2023-01-13 | 2026-02-03 | プールベグ ファーマ（ユーケー） リミテッド | がん免疫療法関連サイトカイン放出症候群の軽減のための医薬品および方法 |
| WO2025093869A1 (en) * | 2023-11-01 | 2025-05-08 | Poolbeg Pharma (UK) Limited | P38 map kinase inhibitor for use in the treatment of inflammation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008141057A1 (en) * | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals, Inc. | Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea |
| JP5466759B2 (ja) * | 2009-05-28 | 2014-04-09 | ノバルティス アーゲー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
| US8575348B2 (en) * | 2009-07-28 | 2013-11-05 | Auspex Pharmaceuticals, Inc | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
| US9359300B2 (en) * | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| SI2648516T1 (sl) * | 2010-12-06 | 2019-01-31 | Aclaris Therapeutics, Inc. | Substituirane spojine piridinon-piridinila |
| HUE054178T2 (hu) * | 2013-06-07 | 2021-08-30 | Aclaris Therapeutics Inc | Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek |
| CZ2015601A3 (cs) * | 2015-09-02 | 2017-03-15 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty |
| EP3442940A1 (en) * | 2016-04-11 | 2019-02-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| WO2018229683A1 (en) * | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| EP3720436A4 (en) | 2017-12-06 | 2021-06-02 | Lin Bioscience, Pty Ltd. | TUBULIN INHIBITORS |
| US20230087078A1 (en) | 2020-03-02 | 2023-03-23 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
-
2020
- 2020-07-31 JP JP2022506384A patent/JP2022542434A/ja not_active Ceased
- 2020-07-31 WO PCT/US2020/044558 patent/WO2021022186A1/en not_active Ceased
- 2020-07-31 PH PH1/2022/550029A patent/PH12022550029A1/en unknown
- 2020-07-31 BR BR112022001324A patent/BR112022001324A2/pt not_active IP Right Cessation
- 2020-07-31 CA CA3149304A patent/CA3149304A1/en active Pending
- 2020-07-31 EP EP20847487.4A patent/EP4003344A4/en active Pending
- 2020-07-31 CN CN202080051376.9A patent/CN114206339A/zh active Pending
- 2020-07-31 MX MX2022001151A patent/MX2022001151A/es unknown
- 2020-07-31 AU AU2020319879A patent/AU2020319879A1/en not_active Abandoned
- 2020-07-31 US US17/630,414 patent/US12403141B2/en active Active
- 2020-07-31 KR KR1020227006713A patent/KR20220041180A/ko active Pending
-
2022
- 2022-01-23 IL IL290045A patent/IL290045A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542434A5 (enExample) | ||
| JP2022531088A5 (enExample) | ||
| JP2021534244A5 (enExample) | ||
| ES2985542T3 (es) | Compuesto inhibidor de JAK y uso del mismo | |
| JP7580136B2 (ja) | Ｊａｋ阻害剤化合物及びその使用 | |
| RU2124016C1 (ru) | Пиразолопиримидины и их фармацевтически приемлемые соли | |
| AU2017296295B2 (en) | C7, C12, and C16 substituted neuroactive steroids and their methods of use | |
| JP2021502400A5 (enExample) | ||
| ES2277858T3 (es) | Heterociclos de nitrogeno biciclicos alquilamino sustituidos como inhibidores de proteina kinasa p38. | |
| JP2022137194A (ja) | 神経刺激性ステロイド、組成物、およびその使用 | |
| JP2020128420A (ja) | Ｃｎｓ障害を処置するための組成物および方法 | |
| DE69920732T2 (de) | Bicyclische stickstoffheteroaryl verbindungen | |
| CN109153678B (zh) | 作为fgfr4抑制剂的杂环化合物 | |
| ES2430210T3 (es) | Derivados de 4-aminopirimidina como antagonistas del receptor de histamina H4 | |
| EP3864022B1 (en) | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders | |
| JP2011519936A (ja) | ニューロンニコチン受容体のための選択的リガンドおよびこれらの使用 | |
| JP2017529367A5 (enExample) | ||
| EA027879B1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) | |
| CN113993585B (zh) | 双环jak抑制剂及其用途 | |
| JP2022551316A5 (enExample) | ||
| AU2023270260A1 (en) | Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators | |
| TW202115034A (zh) | 介導酪氨酸激酶2活性的雜環化合物 | |
| JPS5962572A (ja) | グアニジン誘導体の製造方法 | |
| WO2011076878A1 (en) | Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists | |
| WO2022033532A1 (zh) | 一种fgfr及其突变抑制剂，其制备方法和应用 |